Bladder Cancer and Upper Tract Urothelial Carcinoma – Unmet Need – Unmet Need – Unresectable Locally Advanced or Metastatic Bladder Cancer (US/EU)

The unresectable locally advanced or metastatic bladder cancer treatment landscape continues to evolve, driven by the integration of immunotherapy, targeted agents, and antibody–drug conjugates (ADCs). Firstline practice is being reshaped as Padcev (Pfizer) + Keytruda (Merck & Co.) gains momentum, reducing reliance on platinum chemotherapy. Meanwhile, monotherapies such as Keytruda, Opdivo (Bristol Myers Squibb), and Bavencio (Merck KGaA/Pfizer) remain integral but face evolving competitive pressures. Padcev’s first-line shift and Trodelvy’s (Gilead) withdrawal have created a later-line ADC gap. Against this evolving backdrop, targeted agents, including the FGFR inhibitor Balversa (J&J), offer options for select patient populations, underscoring the growing relevance of molecular profiling. However, challenges persist around safety management, durability of benefit, and optimal sequencing. As pricing, efficacy considerations, and formulation innovations (IV/SC) increasingly influence prescribing, our unmet need content provides insights into the perception of key therapies, treatment gaps, and opportunities for emerging therapies.

QUESTIONS ANSWERED

• What are the key factors that drive medical oncologists’ prescribing decisions for this population?
• How do oncologists evaluate the performance of existing therapies across key clinical and nonclinical attributes?
• What are the most significant gaps in the treatment landscape of unresectable locally advanced or metastatic bladder cancer?
• What trade-offs are oncologists willing to make between clinical attributes and price when selecting a treatment regimen?

PRODUCT DESCRIPTION

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.

Geography: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in February 2026

Key companies: Merck & Co., Bristol Myers Squibb, Merck KGaA, Pfizer, Astellas, Johnson & Johnson

Key drugs: Padcev, Keytruda, Opdivo, Bavencio, Balversa